The Official Journal of EuroPCR and the European Association of Percutaneous Coronary Interventions (EAPCI)
Three-year clinical outcome of percutaneous treatment of bifurcation lesions in multivessel coronary artery disease with the sirolimus-eluting stent: insights from the Arterial Revascularisation Therapies Study, part II (ARTS II)
Helen C. Routledge1, MD; Thierry Lefèvre1*, MD; Antonio Colombo2, MD; Keith G. Oldroyd3, MD; Christian W. Hamm4, MD; Giulio Guagliumi5, MD; Wolfgang von Scheidt6, MD; Victor Guetta7, MD; Witold Ruzyllo8, MD; Kristel Wittebols9, MSc; Dick M. Goedhart10, PhD; Patrick W. Serruys11, MD, PhD
1. Institut Cardiovasculaire Paris Sud, Massy, France; 2. EMO Centro Cuore Colombus and San Rafaele Hospital, Milan, Italy; 3. Lanarkshire Acute Hospitals, Glasgow, United Kingdom; 4. Kerckhoff Klinik, Kardiologie, Bad Nauheim, Germany; 5. Azienda Ospedal
Aims: The long-term impact of treating bifurcation lesions on the overall outcome of patients with multivessel coronary disease treated percutaneously with drug-eluting stents is unknown. This analysis determined the influence of bifurcation treatment using sirolimus-eluting stents on 3-year clinical outcomes.
Methods and results: Of the 607 patients (2,160 lesions) in the ARTS II study, 324 patients underwent revascularisation procedures involving treatment of at least one bifurcation (465 lesions). Three-year outcomes were compared to those without bifurcations. Despite more diffuse and complex disease in the bifurcation group, survival free of adverse events was equivalent in the two groups. At 3-years, there was ...